Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7965276 | 0.86 | HSPB1 (0.40) | MAPTPOLBMAPK1RAB9A | |
| SCHEMBL7971836 | 0.76 | APP (0.49) | MAPTPOLBCA9RAB9A | |
| SCHEMBL7968670 | 0.76 | KIF11 (0.42) | KIF11POLBHSD11B1 | |
| SCHEMBL5430351 | 0.76 | CA1 (0.55) | KIF11MAPTSCN2ACA1CA2 | |
| SCHEMBL7966269 | 0.74 | LMNA (0.40) | MAPTPOLBCA9RAB9A | |
| SCHEMBL6932670 | 0.74 | MDM2 (0.38) | MAPTPOLBRAB9A | |
| SCHEMBL6932932 | 0.73 | MDM2 (0.38) | MAPTRAB9A | |
| SCHEMBL6026229 | 0.72 | ADK (0.39) | MAPTPOLBMAPK1CA1CA2 | |
| SCHEMBL6932601 | 0.72 | CFTR (0.43) | MAPTPOLB | |
| Trifluoromethylbenzene SCHEMBL29273876 | 0.71 | KIF11 (0.55) | ABCG2KIF11MAPTSCN2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020141956-A1 | Skin whiteners containing hydroxytetronic acid derivatives | THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY, AS ADMINISTRATIVE AGENT | 2002-10-03 | — | — | US | disclosed |
| US-6265436-B1 | ANTIINFLAMMATORY AGENTS | OXIS THERAPEUTICS INC. | 2001-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020141956-A1 | Skin whiteners containing hydroxytetronic acid derivatives | TYR, PPP6C, CYP26A1 | ABCG2 2240/4885KIF11 2193/4885MAPT 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.